Table II.
Locally advanced basal cell carcinoma (laBCC) history (n = 21)
| All patients | |
|---|---|
| Age at LaBCC diagnosis, years, n (missing) | 21 (0) |
| Median (range) | 71.5 (19.1; 88.8) |
| Time between LaBCC diagnosis and Sonidegib initiation, months, n (missing) | 21 (0) |
| Median (range) | 3.7 (0.7; 322.4) |
| Location of the target lesion, n/N (%) | |
| Head | 20/21 (95.2) |
| Other | 1/21 (4.8) |
| Presence of non-target lesions: yes, n/N (%) | 6/21 (28.6) |
| Histological subtypes, n = 21, n/N (%) | |
| Agressive | 13/21 (61.9) |
| Micronodular | 0/13 (0.0) |
| Infiltrative | 11/13 (84.6) |
| Multifocal | 0/13 (0.0) |
| Basosquamous | 0/13 (0.0) |
| Sclerosing | 2/13 (15.4) |
| Non-agressive | 2/21 (9.5) |
| Nodular | 2/2 (100.0) |
| Superficial | 0/2 (0.0) |
| Not evaluable | 5/21 (23.8) |
| Unknown | 1/21 (4.8) |
| Treatment before Sonidegib (n=21), n/N (%) | |
| Surgical excision | 8/21 (38.1) |
| Pharmacological treatment | 3/21 (14.3) |
| Hedgehog inhibitor | 3/3 |
| Chemotherapy | 1/3 |
| Other | 0/3 |
| Topical treatment, n/N (%) | 1/21 (4.8) |
| 5-fluorouracil / Imiquimod | 1/1 |
| Photodynamic therapy, n/N (%) | 1/21 (4.8) |
| Electro-cauterization, n/N (%) | 0/21 (0.0) |
| Other, n/N (%) | 0/21 (0.0) |